Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Czech Republic: Strepto-Fatol; France: Streptomycine; Germany: Strepto-Fatol, StreptoHefa, Streptomycin; Greece: Streptomycin; Italy: Strep S; Latvia: Streptomycin; Lithuania: Streptomycin; Poland: Streptomycinum; Portugal: Estreptomicina; Romania: Strevital; Spain: Estreptomicina.

North America

USA: Streptomycin Sulphate.

Latin America

Argentina: Estreptomicina; Mexico: Bucomicina, Estrefén, Sulfestrep.


Japan: Streptomycin.

Drug combinations

Streptomycin and Neomycin

Streptomycin, Nitrofurazone, and Tyrothricin

Streptomycin, Clotrimazole, Nitrofurazone, and Tyrothricin


Streptomycin Sulfate: (C~21~H~39~N~7~O~12~)~2~ 3H~2~SO~4~. Mw: 1457.38. D-Streptamine, O-2-deoxy-2-(methylamino)-α-L-glucopyranosyl-(1→2)-O-5-deoxy-3-C-formyl-α-L-lyxofuranosyl-(1→4)-N,N’-bis(aminoiminomethyl)-, sulfate (2:3). CAS-3810-74-0; CAS-57-92-1 (streptomycin).

Pharmacologic Category

Antibacterials; Aminoglycosides. Antituberculosis Agents. (ATC-Code: A07AA04; J01GA01).

Mechanism of action

Usually bactericidal. Inhibits protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits. Active in vitro against Gram-positive aerobes such as Erysipelothrix, Enterococcus faecalis, Nocardia, and Streptococcus viridans. Active in vitro and in clinical infections against Gram-negative aerobes such as Brucella, Enterobacter aerogenes, Escherichia coli, Francisella tularensis, Haemophilus ducreyi, H. influenzae, Klebsiella granulomatis (formerly Calymmatobacterium granulomatis), Klebsiella pneumoniae, Pasteurella multocida, Proteus, and Yersinia pestis. Active against mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. genavense, and some strains of M. avium complex, M. kansasii, M. malmoense, M. marinum, M. szulgai, and M. ulcerans. Partial cross-resistance occurs between streptomycin and other aminoglycosides. Inactive against fungi, viruses, and most anaerobic bacteria.

Therapeutic use

Active tuberculosis. Streptococcal or enterococcal endocarditis, mycobacterial infections, plague, tularemia, and brucellosis.

Pregnancy and lactiation implications

Streptomycin crosses placenta. Many case reports published of hearing impairment in children exposed in utero. Enters breast milk (not recommended in nursing women).

Unlabeled use


Hypersensitivity to streptomycin or any component of the formulation. Pregnancy.

Warnings and precautions

May cause nephrotoxicity. May cause neuromuscular blockade and respiratory paralysis. May cause neurotoxicity. Ototoxicity proportional to amount of drug given and duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Parenteral form should be used only where appropriate audiometric and laboratory testing facilities are available. False-positive urine glucose with Benedict’s solution. Penicillin may decrease aminoglycoside serum concentrations in vitro.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart